TY  - JOUR
AU  - Alcázar-Navarrete, Bernardino
AU  - Jamart, Lucía
AU  - Sánchez-Covisa, Joaquín
AU  - Juárez, Mónica
AU  - Graefenhain, Ruth
AU  - Sicras-Mainar, Antoni
PY  - 2022
DO  - 10.1016/j.chest.2022.06.033
UR  - http://hdl.handle.net/10668/22088
T2  - Chest
AB  - COPD is a leading cause of death and disability. COPD therapy goals include reducing exacerbations and improving symptom control. Single-inhaler triple therapy (SITT) or multiple-inhaler triple therapy (MITT) is indicated for patients with frequent...
LA  - en
KW  - COPD
KW  - fixed-dose combinations
KW  - inhaled corticosteroids (ICS)
KW  - long-acting muscarinic antagonists (LAMA)
KW  - long-acting β2-agonists (LABA)
KW  - multiple-inhaler triple therapy (MITT)
KW  - persistence
KW  - single-inhaler triple therapy (SITT)
KW  - Humans
KW  - Male
KW  - Aged
KW  - Female
KW  - Adrenergic beta-2 Receptor Agonists
KW  - Muscarinic Antagonists
KW  - Retrospective Studies
KW  - Pulmonary Disease, Chronic Obstructive
KW  - Spain
KW  - Adrenal Cortex Hormones
KW  - Disease Progression
KW  - Nebulizers and Vaporizers
KW  - Administration, Inhalation
KW  - Bronchodilator Agents
TI  - Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain.
TY  - research article
VL  - 162
ER  -